Why the study?
Does continuous-pump heparin therapy monitored by activated coagulation time safely and effectively treat patients with venous thrombosis or pulmonary embolism?
Does continuous-pump heparin therapy monitored by activated coagulation time safely and effectively treat patients with venous thrombosis or pulmonary embolism?
A protocol of continuous-pump heparin therapy monitored by activated coagulation time is successful and safe for treating thromboembolic disorders when followed closely.
Emphasizes precise heparin dosing to minimize bleeding; leaves open confirmation of safety and efficacy in randomized trials.
One hundred thirty-four patients with venous thrombosis or pulmonary embolism, confirmed by radiological techniques, received continuous-pump heparin therapy while their responses were monitored by the activated coagulation time (ACT). The suggested protocol was as follows: (1) give an intravenous bolus of about 50 units/kg; (2) follow with 15 to 25 units/kg/hr; (3) modify infusion rate to maintain ACT of 150 to 190 s; (4) after two or three days with ACT in target range, start oral warfarin sodium therapy; (5) after three to five days of warfarin therapy, if prothrombin time is two to 2 1/2 times the control value, discontinue heparin administration. One hundred thirty-two patients responded, with no heparin failures. Dangerous bleeding occurred in two who received excessive amounts of heparin. Some patients, mostly with short ACTs, responded slowly; some, many with long ACTs, had minor bleeding. The protocol proved successful and safe when followed closely.
No takes yet. Share an insight, caveat, or question.
Paul G. Hattersley (1983) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: